Treatment of Ocular Inflammatory Disorders With Daclizumab

Ophthalmology. 2003 Apr;110(4):786-9. doi: 10.1016/S0161-6420(02)01932-2.

Abstract

Purpose: To evaluate the efficacy and safety of daclizumab therapy for patients with various ophthalmologic inflammatory disorders (all having previously failed standard treatment methods).

Design: Retrospective, nonrandomized case series.

Participants: Fourteen patients.

Methods: Fourteen patients were treated with daclizumab after previously failing standard treatment methods.

Main outcome measures: Inflammation and visual acuity.

Results: Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened.

Conclusions: Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.

Publication types

  • Clinical Trial
  • Evaluation Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Child
  • Conjunctivitis / drug therapy*
  • Daclizumab
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Pemphigoid, Benign Mucous Membrane / drug therapy*
  • Scleritis / drug therapy*
  • Treatment Outcome
  • Uveitis / drug therapy*
  • Visual Acuity

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab